The approval of the Ministry of Health for Maccabi to delay the introduction of orphan drugs into the supplementary insurance raises concerns about harm to patients with rare diseases and the expansion of the move in the future • Maccabi claims that this is a step designed to facilitate negotiations with the pharmaceutical companies and maintain the stability of the supplementary insurance